Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (NCT02191930)
The purpose of this trial is to determine:
- Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
- Progression-free survival (PFS) 3 years after registration
This trial is sponsored by University of Cologne. 
- Condition: Hodgkin Lymphoma
- Phase: II
- Estimated Enrollment: 70
- Start: September 2014
- Estimated Primary Completion: September 2015
- Last verified: July 2014
Click here for an overview of other trials with brentuximab vedotion.
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.